Business, energy, technology, markets and global industry news from Business News Today

European Hematology Association

PharmaDeviceNews European Hematology Association
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
Representative image of hematology research and blood sample analysis, reflecting Cogent Biosciences’ bezuclastinib NDA for advanced systemic mastocytosis and the APEX trial data supporting a potential new FDA treatment option for KIT-driven mast cell disease.
Pharma & Biotech

Cogent advances third bezuclastinib FDA submission after APEX pivotal trial results

Cogent’s bezuclastinib NDA for advanced systemic mastocytosis is backed by APEX data showing 65% ORR and deep KIT-driven disease marker reductions.

Read More
A hematology specialist reviews red blood cell findings as Johnson & Johnson advances nipocalimab as a potential first targeted treatment for warm autoimmune hemolytic anemia. Representative image.
Pharma & Biotech

Johnson & Johnson strengthens nipocalimab’s FDA case with rapid hemoglobin improvement

The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.

Read More
Representative image of blood testing in a clinical laboratory, reflecting coverage of Agios Pharmaceuticals’ mitapivat Phase 3 RISE UP data and the evolving sickle cell disease treatment debate.
Pharma & Biotech

Why mitapivat’s Phase 3 data could change the sickle cell disease treatment debate

Find out how Agios’ mitapivat Phase 3 data could shape the next treatment debate in sickle cell disease care.

Read More
Representative image of hematology research and blood sample analysis, reflecting AbbVie’s long-term Venclexta data in first-line chronic lymphocytic leukemia treatment.
Pharma & Biotech

AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus

Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.

Read More
Representative image: A clinician reviews blood disorder data in a hospital setting, reflecting Johnson & Johnson’s IMAAVY Phase 2/3 results and the growing focus on FcRn-targeted treatment for warm autoimmune hemolytic anemia.
Pharma & Biotech

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.

Read More